Hidradenitis suppurativa: Current and emerging treatments

J Am Acad Dermatol. 2020 May;82(5):1061-1082. doi: 10.1016/j.jaad.2019.08.089. Epub 2019 Oct 9.

Abstract

The treatment of hidradenitis suppurativa (HS) has remained challenging because of the many knowledge gaps regarding etiology. However, recent studies into the pathogenesis of HS have enabled the investigation of newer therapies. The second article in this continuing medical education series reviews the evidence for established therapies for HS, including anti-inflammatories, antibiotics, and surgery. New and emerging therapies that specifically target cytokines involved in HS pathogenesis will be covered. The potential therapeutic roles of anticytokine therapies, including both the expanded application of existing molecules as well as the specific development of novel therapies for HS are discussed. With increased attention on HS and with numerous clinical trials currently underway, we hope that the variety of treatment options for HS will be expanded.

Keywords: adalimumab; antibiotics; hidradenitis; secukinumab; ustekinumab.

Publication types

  • Review

MeSH terms

  • Adalimumab / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Inflammatory Agents / therapeutic use*
  • Education, Medical, Continuing
  • Female
  • Hidradenitis Suppurativa / diagnosis
  • Hidradenitis Suppurativa / therapy*
  • Humans
  • Laser Therapy / methods*
  • Male
  • Pain Measurement
  • Quality of Life*
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab